tetano
Editor, Senior Moderator
Cells
. 2022 Mar 8;11(6):922.
doi: 10.3390/cells11060922.
Biomarkers Associated with Cardiovascular Disease in COVID-19
Christoph C Kaufmann[SUP] 1 [/SUP], Amro Ahmed[SUP] 1 [/SUP], Achim Leo Burger[SUP] 1 [/SUP], Marie Muthspiel[SUP] 1 [/SUP], Bernhard Jäger[SUP] 1 2 [/SUP], Johann Wojta[SUP] 3 4 5 [/SUP], Kurt Huber[SUP] 1 2 5 [/SUP]
Affiliations
Abstract
Coronavirus disease-19 (COVID-19) emerged late December 2019 in the city of Wuhan, China and has since spread rapidly all over the world causing a global pandemic. While the respiratory system is the primary target of disease manifestation, COVID-19 has been shown to also affect several other organs, making it a rather complex, multi-system disease. As such, cardiovascular involvement has been a topic of discussion since the beginning of the COVID-19 pandemic, primarily due to early reports of excessive myocardial injury in these patients. Treating physicians are faced with multiple challenges in the management and early triage of patients with COVID-19, as disease severity is highly variable ranging from an asymptomatic infection to critical cases rapidly deteriorating to intensive care treatment or even fatality. Laboratory biomarkers provide important prognostic information which can guide decision making in the emergency department, especially in patients with atypical presentations. Several cardiac biomarkers, most notably high-sensitive cardiac troponin (hs-cTn) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), have emerged as valuable predictors of prognosis in patients with COVID-19. The purpose of this review was to offer a concise summary on prognostic cardiac biomarkers in COVID-19 and discuss whether routine measurements of these biomarkers are warranted upon hospital admission.
Keywords: BNP; COVID-19; cardiac biomarkers; myocardial injury; troponin.
. 2022 Mar 8;11(6):922.
doi: 10.3390/cells11060922.
Biomarkers Associated with Cardiovascular Disease in COVID-19
Christoph C Kaufmann[SUP] 1 [/SUP], Amro Ahmed[SUP] 1 [/SUP], Achim Leo Burger[SUP] 1 [/SUP], Marie Muthspiel[SUP] 1 [/SUP], Bernhard Jäger[SUP] 1 2 [/SUP], Johann Wojta[SUP] 3 4 5 [/SUP], Kurt Huber[SUP] 1 2 5 [/SUP]
Affiliations
- PMID: 35326373
- DOI: 10.3390/cells11060922
Abstract
Coronavirus disease-19 (COVID-19) emerged late December 2019 in the city of Wuhan, China and has since spread rapidly all over the world causing a global pandemic. While the respiratory system is the primary target of disease manifestation, COVID-19 has been shown to also affect several other organs, making it a rather complex, multi-system disease. As such, cardiovascular involvement has been a topic of discussion since the beginning of the COVID-19 pandemic, primarily due to early reports of excessive myocardial injury in these patients. Treating physicians are faced with multiple challenges in the management and early triage of patients with COVID-19, as disease severity is highly variable ranging from an asymptomatic infection to critical cases rapidly deteriorating to intensive care treatment or even fatality. Laboratory biomarkers provide important prognostic information which can guide decision making in the emergency department, especially in patients with atypical presentations. Several cardiac biomarkers, most notably high-sensitive cardiac troponin (hs-cTn) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), have emerged as valuable predictors of prognosis in patients with COVID-19. The purpose of this review was to offer a concise summary on prognostic cardiac biomarkers in COVID-19 and discuss whether routine measurements of these biomarkers are warranted upon hospital admission.
Keywords: BNP; COVID-19; cardiac biomarkers; myocardial injury; troponin.